KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Free Cash Flow (2016 - 2025)

Arbutus Biopharma's Free Cash Flow history spans 13 years, with the latest figure at -$5.8 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 71.95% year-over-year to -$5.8 million; the TTM value through Sep 2025 reached -$45.4 million, up 36.94%, while the annual FY2024 figure was -$65.0 million, 25.2% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$5.8 million at Arbutus Biopharma, up from -$15.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $20.5 million in Q1 2022 and bottomed at -$27.4 million in Q1 2023.
  • The 5-year median for Free Cash Flow is -$17.3 million (2023), against an average of -$15.3 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 214.26% in 2022 before it tumbled 233.46% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$19.7 million in 2021, then increased by 12.92% to -$17.1 million in 2022, then fell by 0.98% to -$17.3 million in 2023, then surged by 39.85% to -$10.4 million in 2024, then soared by 44.07% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Free Cash Flow are -$5.8 million (Q3 2025), -$15.7 million (Q2 2025), and -$13.4 million (Q1 2025).